Promising Results for Depression Treatment with Microdosing LSD

August 27, 2024 Lynne Nardizzi

MindBio Therapeutics Corp. (CSE) has recently unveiled promising durability data from its Phase 2A clinical trials, which tested MB22001, the company’s innovative self-administered, take-home microdose of Lysergic Acid Diethylamide (LSD), as a treatment for depression.

This development underscores MindBio’s commitment to advancing psychedelic medicine as a viable option for mental health treatment.

LSD for Anxiety?

April 25, 2024 Lynne Nardizzi

The government finally fast-tracked LSD as an anxiety treatment.

MindMed, the first publicly traded pharmaceutical company focused on psychedelics, said its drug has received a breakthrough designation from the FDA.

Comparing MDMA and LSD

February 9, 2024 Lynne Nardizzi

Different psychedelics show unique promise for treating mental illness, from PTSD to depression and anxiety. This article compares MDMA and LSD.

LSD and Brain Connections

June 13, 2023 Lynne Nardizzi

This study, published in the Journal of Psychopharmacology, found that LSD “not only increases the strength of certain brain connections but weakens other connections at the same time,” according to a digest of the study in Psychedelic Spotlight.

LSD, Psychosis and Healing

May 18, 2023 Lynne Nardizzi

This study explores the paradoxical relationship connecting key parameters of the psychotic experience, psychotherapy, and psychedelic experience.

The link between psychosis model and therapeutic model seems to lie in mystical experiences.

The results point to the importance of meaning attribution for the LSD psychosis model and indicate that psychedelic-assisted therapy might benefit from therapeutic suggestions fostering mystical experiences.

An LSD Analogue and Therapeutic Potential

May 5, 2023 Lynne Nardizzi

An analogue of LSD (or 2-bromo-LSD) has been demonstrated to produce neuroplastic effects without producing tolerance, a head twitch response, or binding to 5HT2B receptors which is potentially linked to valvular heart disease.

Microdosing LSD - No Long-term Changes Found

May 2, 2023 Lynne Nardizzi

A new study on microdosing LSD did not find any beneficial long-term changes in mood or cognition.

Your Brain on LSD

May 1, 2023 Lynne Nardizzi

In a newly published study, researchers look at what happens to your brain on LSD.

LSD History

April 25, 2023 Lynne Nardizzi

Amanda Feilding, founder and director of The Beckley Foundation, has been at the forefront of scientific research into psychoactive substances and global drug policy reform for the past 50 years.

She was a personal acquaintance of Albert Hofmann, the scientist who first synthesised LSD and noted its psychedelic effects 80 years ago, in April 1943.

Global Survey 2020 Results: Self-Treatment of LSD and Psilocybin

March 19, 2023 Lynne Nardizzi

The Global Drug Survey 2020 is a large online survey on drug use collected between November 2019 and February 2020.

Positive changes were observed across all 17 outcome items, with the strongest benefits on items related to insight and mood. Negative effects were reported by 22.5% of respondents.

High intensity of psychedelic experience, seeking advice before treatment, treating with psilocybin mushrooms and treating post-traumatic stress disorder were associated with higher scores on the self-treatment outcome scale after averaging values across all 17 items.

Younger age, high intensity of experience and treating with LSD were associated with increased number of negative outcomes.

A Non-Hallucinogenic LSD Analog?

March 17, 2023 Lynne Nardizzi

BetterLife Pharma Inc., an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that findings from a study on its lead candidate BETR-001 (2-bromo-LSD) titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders” has been published in the peer-reviewed journal of Cell Report.

What do you think?

Blog